Carcinoma of the cervix is frequently diagnosed in the department of Radiation Oncology in Charlotte Maxeke Johannesburg Academic Hospital(CMJAH). It is therefore is a condition of priority and there is scarce literature in the management of HIV positive patients. OBJECTIVES: The primary objective of the research is to determine the overall survival of 2yrs and more, as well as to determine acute and late toxicity for patients completing prescribed radiation treatment. The secondary objective was to determine the impact of highly active antiretroviral therapy on survival and toxicity. The study is limited to HIV positive women presenting with cervical cancer. DESIGN & METHOD: The study is a retrospective study of patients treated at Charlotte Maxeke Johannesburg Academic Hospital between 2008-2009. Inclusion criteria: Females between the ages of 18 and 70, Stages IB2 – Stage IIIB carcinoma of the cervix who have completed planned radiation therapy with or without chemotherapy. The sample size was 151 patients. RESULTS: The mean age was 42.7yrs. The median CD4 count was 309 and 26.2% had CD4 counts below 200.The majority of patients had either Stage IIB (55.0%) or IIIB (31.8%). The total dose to Point A was a median dose of 74Gy. The majority of patients had either Grade II (38.4%) or III (31.1%) toxicity. Significant association between these adverse events and HAART status was rated as p=0.0008. The most common late complication was cystitis (15.9%). Overall survival at 2 years was 100% for Stage I, 92.8% for Stage II and 96% for Stage III. CONCLUSION: The median age was lower than in the HIV negative patients. The acute complications for those not on HAART, were higher in comparison to patients on HAART. The overall survival at 2 yrs. was above 90% for all stages in this study / GR2018

No description available.

No / Leishmania donovani are the causative agents of visceral leishmaniasis worldwide. Lack of vaccines and emergence of drug resistance warrants the need for improved drug therapy and newer therapeutic intervention strategies against leishmaniasis. In the present study, we have investigated the effect of the natural indoloquinoline alkaloid cryptolepine on L. donovani AG83 promastigotes. Our results show that cryptolepine induces cellular dysfunction in L. donovani promastigotes, which leads to the death of this unicellular parasite. Interestingly, our study suggest that cryptolepine-induced cell death of L. donovani is counteracted by initial autophagic features elicited by the cells. For the first time, we show that autophagy serves as a survival mechanism in response to cryptolepine treatment in L. donovani promastigotes and inhibition of autophagy causes an early increase in the amount of cell death. This study can be exploited for designing better drugs and better therapeutic strategies against leishmaniasis in future.

by Mei Choi Tang. / Thesis submitted in 1997. / Thesis (M.Phil.)--Chinese University of Hong Kong, 1998. / Includes bibliographical references. / Abstract also in Chinese. / Chapter Chapter 1. --- Introduction --- p.1-22 / Chapter Chapter 2. --- PAE studies for antimicrobial combinations using the Fractional Maximal Effect method (FME method) --- p.23-64 / Chapter Chapter 3. --- Effect of sequential antibiotic administration on the postantibiotic effect exhibited by an antimicrobial combination: A case for the combination of rifampin and tobramycin against E.coli ATCC 25922 --- p.65-84 / Chapter Chapter 4. --- Effect of antimicrobial resistance to the components of an antimicrobial combination: A pilot study with piperacillin and gentamicin against Ps. aeruginosa --- p.85-100 / Chapter Chapter 5. --- Conclusions --- p.101-106 / Appendix I --- p.107-113 / Appendix II --- p.114-116 / Appendix III --- p.117-120 / Appendix IV --- p.121-138 / Appendix V --- p.139-153

Choi Pui-yu. / Thesis (M.Phil.)--Chinese University of Hong Kong, 2002. / Includes bibliographical references (leaves 113-123). / Abstracts in English and Chinese. / Abstract --- p.i / Abstract (Chinese Version) --- p.iii / Acknowledgements --- p.v / List of Abbreviations --- p.vi / Table of Contents --- p.viii / List of Tables --- p.xii / List of Figures --- p.xiii / Chapter Chapter 1 --- Introduction --- p.1 / Chapter Chapter 2 --- Literature Review / Chapter 2.1 --- Mushroom Polysaccharides with Antitumor Activities --- p.7 / Chapter 2.1.1 --- Antitumor β-Glucans --- p.7 / Chapter 2.1.2 --- Antitumor Heteroglycans --- p.9 / Chapter 2.1.3 --- Antitumor Polysaccharide-Protein Complexes --- p.12 / Chapter 2.2 --- Antitumor Activities and Structural Characteristics of Mushroom Polysaccharides --- p.15 / Chapter 2.3 --- Antitumor Effects of Mushroom Polysaccharides In Vitro --- p.19 / Chapter 2.4 --- Antitumor Effects of Mushroom Polysaccharides In Vivo --- p.21 / Chapter 2.5 --- Immunomodulatory Activities --- p.24 / Chapter 2.6 --- Activation of Cytokines by Mushroom Polysaccharides --- p.28 / Chapter 2.7 --- Induction of Nitric Oxide Synthase by Mushroom Polysaccharides --- p.32 / Chapter 2.8 --- Tremella aurantialba --- p.34 / Chapter Chapter 3 --- Materials and Methods --- p.35 / Chapter 3.1 --- Extraction --- p.35 / Chapter 3.1.1 --- Extraction of Crude Tremella aurantialba Polysaccharide --- p.35 / Chapter 3.1.2 --- Fractionation --- p.38 / Chapter 3.1.3 --- Polysaccharide and Protein Content Determination --- p.38 / Chapter 3.1.3.1 --- Phenol-Sulfuric Assay --- p.39 / Chapter 3.1.3.2 --- Lowry-Folin Method --- p.39 / Chapter 3.1.4 --- Gas Chromatography (GC) --- p.40 / Chapter 3.1.5 --- Modified Carbazole Assay --- p.41 / Chapter 3.1.6 --- High Performance Liquid Chromatography (HPLC) --- p.42 / Chapter 3.2 --- In Vitro Studies --- p.43 / Chapter 3.2.1 --- Maintenance of Cell Lines --- p.43 / Chapter 3.2.2 --- Effect on Cancer Cell Lines --- p.43 / Chapter 3.2.2.1 --- Trypan Blue Exclusion Methods --- p.44 / Chapter 3.2.2.2 --- MTT Assay --- p.44 / Chapter 3.2.3 --- Effect on Normal Cell Line --- p.45 / Chapter 3.2.4 --- Coulter Counter --- p.46 / Chapter 3.3 --- In Vivo Studies --- p.47 / Chapter 3.3.1 --- Animals --- p.47 / Chapter 3.3.2 --- Maintenance of Sarcoma 180 Cell Line --- p.47 / Chapter 3.3.3 --- Effect of TAP Fractions on Sarcoma 18 Solid Tumor --- p.48 / Chapter 3.3.3.1 --- Injection of TAP Fractions 24 h After Transplantation --- p.48 / Chapter 3.3.3.2 --- Injection of TAP Fractions 72 h After Transplantation --- p.49 / Chapter 3.4 --- Effect of TAP Fractions on Modulating mRNA Expression of Cytokines and Nitric Oxide Synthase --- p.51 / Chapter 3.4.1 --- Treatment of Mice --- p.51 / Chapter 3.4.2 --- Isolation of Splenocytes and Peritoneal Exduate Cells --- p.51 / Chapter 3.4.3 --- Extraction of Total mRNA from Splenocyte and Peritoneal Exduate Cells --- p.52 / Chapter 3.4.4 --- Reverse Transcription-Polymerase Chain Reaction (RT-PCR) --- p.53 / Chapter 3.4.4.1 --- Reverse Transcription --- p.53 / Chapter 3.4.4.2 --- Polymerase Chain Reaction --- p.56 / Chapter 3.4.5 --- DNA Sequencing --- p.57 / Chapter 3.5 --- Statistical Analysis --- p.58 / Chapter Chapter 4 --- Results --- p.59 / Chapter 4.1 --- Isolation and Characterization of TAP Fractions --- p.59 / Chapter 4.1.1 --- Percentage Yield of TAP Fractions --- p.59 / Chapter 4.1.2 --- Polysaccharide and Protein Content of TAP Fractions --- p.59 / Chapter 4.1.3 --- Relative Monosaccharide Contents in TAP Fractions --- p.60 / Chapter 4.1.4 --- Results of HPLC --- p.60 / Chapter 4.2 --- Effects of TAP Fractions In Vitro --- p.69 / Chapter 4.2.1 --- Effects of TAP Fractions on Suspension Cancer Cell Lines --- p.69 / Chapter 4.2.2 --- Effects of TAP Fractions on Adhesion Cancer Cell Lines --- p.69 / Chapter 4.2.3 --- Effects of TAP Fractions on Normal Cell Line --- p.70 / Chapter 4.2.4 --- Effect of TAP 2 on HL-60 Cell Line as Evaluated by Coulter Counter --- p.70 / Chapter 4.3 --- Antitumor Effect of TAP Fractions In Vivo --- p.78 / Chapter 4.4 --- Effect of TAP Fractions on Modulating mRNA Expressions of Cytokines and Nitric Oxide Sythase (NOS) --- p.83 / Chapter 4.4.1 --- Results of RT-PCR --- p.83 / Chapter 4.4.2 --- Sequencing --- p.84 / Chapter Chapter 5 --- Discussion --- p.91 / Chapter 5.1 --- Characterization of TAP Fractions --- p.91 / Chapter 5.2 --- Antitumor Effects of TAP Fractions In Vitro --- p.96 / Chapter 5.3 --- Furhter Study --- p.109 / Chapter Chapter 6 --- Conclusion --- p.111 / References --- p.113

Poon Shuk-ching. / Thesis (M.Phil.)--Chinese University of Hong Kong, 2002. / Includes bibliographical references (leaves 113-125). / Abstracts in English and Chinese. / Acknowledgements --- p.i / Abstract --- p.ii / Abstract (Chinese Version) --- p.iv / Table of Contents --- p.vi / List of Tables --- p.x / List of Figures --- p.xi / List of Abbreviations --- p.xiii / Chapter Chapterl 1 --- ntroduction --- p.1 / Chapter Chapter 2 --- Literature Review --- p.5 / Chapter 2.1 --- Mushroom Polysaccharides From Basidiomycetes --- p.5 / Chapter 2.1.1 --- Antitumor and Immunomodulatory Activity --- p.6 / Chapter 2.1.2 --- Antiviral Activity --- p.9 / Chapter 2.1.3 --- Hypoglycermic Activity --- p.11 / Chapter 2.1.4 --- Free Radical Scavenging Activity --- p.11 / Chapter 2.2 --- Mushroom Dictyophora indusiata --- p.13 / Chapter 2.2.1 --- Nutritional Value --- p.13 / Chapter 2.2.2 --- Structural Characteristic of Dictyophora indusiata Polysaccharides --- p.14 / Chapter 2.2.3 --- Biological Activity --- p.16 / Chapter 2.3 --- In vivo Antitumor Study --- p.19 / Chapter 2.4 --- Induction of Cytokines Production in Immune System --- p.21 / Chapter 2.5 --- In vitro Antitumor Study --- p.25 / Chapter 2.6 --- Cell Cycle Regulation --- p.28 / Chapter Chapter 3 --- Materials & Methods --- p.34 / Chapter 3.1 --- Extraction --- p.34 / Chapter 3.1.1 --- Extraction of Dictyophora indusiata Polysaccharides --- p.34 / Chapter 3.1.2 --- Purification of Dictyophora indusiata Polysaccharides --- p.35 / Chapter 3.1.2.1 --- Preparation of DEAE-cellulose Ion Exchanger --- p.35 / Chapter 3.1.2.2 --- Fractionation --- p.35 / Chapter 3.2. --- Characterization of Dictyophora indusiata Polysaccharides --- p.39 / Chapter 3.2.1 --- Polysaccharide Content Determination --- p.39 / Chapter 3.2.2 --- Protein Content Determination --- p.39 / Chapter 3.2.3 --- Gas Chromatography (GC) --- p.40 / Chapter 3.2.4 --- Uronic Acid Content Determination --- p.42 / Chapter 3.2.5 --- High Performance Liquid Chromatography (HPLC) --- p.43 / Chapter 3.3 --- In vivo Studies --- p.44 / Chapter 3.3.1 --- Animals --- p.44 / Chapter 3.3.2 --- Maintenance of Sarcoma 180 Cell Line --- p.44 / Chapter 3.3.3 --- Effect of DI3 Fraction on Sarcoma 180 Solid Tumor --- p.45 / Chapter 3.3.4 --- Effect of DI3c Fraction on Tumor Necrosis Factor-Alpha (TNF-α) and Interleukin 2 (IL-2) Production --- p.47 / Chapter 3.3.4.1 --- Treatment of Mice --- p.47 / Chapter 3.3.4.2 --- Preparation of Mouse Serum --- p.47 / Chapter 3.3.4.3 --- Enzyme-linked Immunosorbent Assay (ELISA) for TNF-α Production --- p.48 / Chapter 3.3.4.4 --- Enzyme-linked Immunosorbent Assay (ELISA) for IL-2 Production --- p.49 / Chapter 3.4 --- In vitro Studies --- p.51 / Chapter 3.4.1 --- Maintenance of Cell Lines --- p.51 / Chapter 3.4.2 --- Effect on Cancer Cell Lines --- p.52 / Chapter 3.4.3 --- Cytotoxicity on Normal Cell Line --- p.52 / Chapter 3.4.4 --- Trypan Blue Exclusion Method --- p.53 / Chapter 3.4.5 --- MTT Assay --- p.54 / Chapter 3.4.6 --- BrdU Incorporation --- p.55 / Chapter 3.5 --- Statistical Analysis --- p.56 / Chapter Chapter 4 --- Results --- p.57 / Chapter 4.1 --- Extraction and Fractionation of Polysaccharides from Dictyophora indusiata --- p.57 / Chapter 4.1.1 --- Percentage Yield of Crude DI Polysaccharides --- p.57 / Chapter 4.1.2 --- Percentage Yield of DI3 Fractions --- p.57 / Chapter 4.2 --- Characterization of DI3 Fractions --- p.62 / Chapter 4.2.1 --- Polysaccharide and Protein Contents of DI3 Fractions --- p.62 / Chapter 4.2.2 --- Relative Monosaccharide and Uronic Acid Content in Different DI3 Fractions --- p.62 / Chapter 4.2.3 --- Estimated Molecular Weight of DI3 Fractions --- p.65 / Chapter 4.3 --- Antitumor Effect of Dictyophora indusiata Polysaccharides In vivo --- p.70 / Chapter 4.3.1 --- In vivo Antitumor Effect of Crude DI Polysaccharides --- p.70 / Chapter 4.3.2 --- In vivo Antitumor Effect of Various Fractions of DI3 --- p.70 / Chapter 4.3.3 --- Effect of DI3c on TNP-α and IL-2 Production in Mice --- p.78 / Chapter 4.4 --- In vitro Effects of DI3 Fractions on Cell Density and Viability on Normal and Cancer Cell Lines --- p.86 / Chapter 4.4.1 --- Effects of DI3 Fractions on Cell Density and Viability of Human Leukemic HL-60 and K-562 and Mouse Sarcoma 180 Cells --- p.86 / Chapter 4.4.2 --- Effects of DI3 Fractions on the Growth of Human Liver Cancer HepG2 and Normal Monkey Kidney Vero Cells --- p.86 / Chapter 4.4.3 --- Effect of DI3b Fraction on Proliferation of HL-60 Cells Determined by BrdU Incorporation --- p.94 / Chapter Chapter 5 --- Discussions --- p.96 / Chapter 5.1 --- Extraction and Characterization of DI3 Fractions --- p.96 / Chapter 5.2 --- Antitumor Effects of Dictyophora indusiata Polysaccharides --- p.101 / Chapter 5.3 --- Further Studies --- p.109 / Chapter Chapter 6 --- Conclusion --- p.111 / References --- p.113

Basing on the traditional TCM interpretation, experience of recent research studies and our experimental findings, a few component herbs in Formulae 1 & 2 would be tentatively selected for a new formula. They were Radix Rehmanniae, Radix Astragali, Rhizoma Atractylodis Macrocephalae, Rhizoma Alismatis, Cortex Moutan and Rhizoma Smilacis Chinensis. Whether the new formula could give better efficacy would need to be tested in new clinical trials and experimental models. (Abstract shortened by UMI.) / Diabetes mellitus has long been a clinical problem for hundreds of years. More than 194 million people in the world now suffer from the disorder. About 15% of all diabetic patients would develop unhealing foot ulcers which compile significant proportion of nontraumatic lower-extremity amputations. Basing on the clinical experience of Prof. Xi Jiu Yi in Shanghai, literature review and an innovative interpretation of traditional Chinese medicine, two formulae (F1 & F2) derived from a well known herbal formula: the "Pills of Six Drugs with Rehmannia" were created for clinical trials. With the early successful limb salvage rate of over 80% observed in a clinical series studied at the Prince of Wales Hospital, Hong Kong, multi-directional studies on the two formulae were carried out. The aim was to find out the clinical efficacy of Formulae 1 & 2, and their component herbs, and the biological mechanism of action. A series of in-vitro, ex-vivo and in-vivo experimental models were completed for the latter purposes. / Granulation formation is an important issue essential for ulcer healing. Therefore a CRL-7522 fibroblast cell line and primary fibrobass from eight diabetic foot ulcer patients (ex-vivo) were used to detect the granulation enhancing activities of the Formulae 1 & 2 and component herbs. The two formulae and some of their component herbs viz, Radix Astragali (HQ), Radix Rehmanniae (SD) and Rhizoma Atractylodis Macrocephalae (BZ) showed significant enhancement effects on the cell viability and apparently facilitated granulation formation. Hence the Formulae 1 & 2, and the three component herbs were selected for further studies. The other nine component herbs of the formulae were found to have no significant enhancing effects on cell viability. With an established diabetic rat model (n0 STZ and n5 STZ), a piece of full-thickness skin was removed from the foot of the rat to develop a diabetic rat foot ulcer model. The ulcer area was measured by a specially designed area measuring programme, namely the Image Analytical Programme. The ulcer areas and their percentage reductions over time were recorded and analysed using statistical multilevel models with adjustments for weight, blood glucose level and the presence of extra ulcers. Results revealed that the ulcer area was significantly reduced by the Formulae 1 & 2, and one of their component herbs, Radix Rehmanniae (SD). / Lau Tai-Wai. / "February 2005." / Adviser: Ping Chung Leung. / Source: Dissertation Abstracts International, Volume: 67-01, Section: B, page: 0197. / Thesis (Ph.D.)--Chinese University of Hong Kong, 2005. / Includes bibliographical references (p. 292-310). / Electronic reproduction. Hong Kong : Chinese University of Hong Kong, [2012] System requirements: Adobe Acrobat Reader. Available via World Wide Web. / Electronic reproduction. [Ann Arbor, MI] : ProQuest Information and Learning, [200-] System requirements: Adobe Acrobat Reader. Available via World Wide Web. / Abstracts in English and Chinese. / School code: 1307.

Thesis (M.S.P.H.)--University of South Florida, 2009. / Title from PDF of title page. Document formatted into pages; contains 57 pages. Includes bibliographical references.

Fusafungine is an antibiotic of fungal origin with a potent local anti-inflammatory action (German-Fattal, 1995; German-Fattal, 1996). It is administered locally to the nasal and pharyngeal mucosa by spray. It can be hypothesised that the anti-inflammatory action of fusafungine may decrease the development of mucosa! inflammation in such a manner that the incidence of symptoms of upper respiratory tract infection may be reduced if it is administered before, during and after completion of an ultramarathon. Furthermore, fusafungine could also reduce the risk of secondary bacterial infection. The potential value of fusafungine in reducing the symptoms of upper respiratory tract infections or the development of bacterial upper respiratory infection is the focus of this thesis.

Grace S.N. Lau. / Thesis (Ph.D.)--Chinese University of Hong Kong, 1994. / Includes bibliographical references (leaves 335-362). / List of Abbreviations --- p.i / Abstract --- p.1 / Chapter Chapter 1 --- General Introduction and Study Objectives / Chapter 1.1 --- Metabolic activation - role in drug toxicity and carcinogenesis --- p.5 / Chapter 1.2 --- Hepatocellular carcinoma --- p.12 / Chapter 1.2.1 --- Epidemiology --- p.12 / Chapter 1.2.2 --- Aetiological factors --- p.17 / Chapter 1.2.2.1 --- Hepatitis B virus infection --- p.17 / Chapter 1.2.2.2 --- Cirrhosis --- p.24 / Chapter 1.2.2.3 --- Aflatoxins --- p.25 / Chapter 1.2.2.4 --- Other factors --- p.26 / Chapter 1.2.2.5 --- Summary --- p.29 / Chapter 1.3 --- Study objectives --- p.30 / Chapter Chapter 2 --- The Metabolism of Paracetamol in Healthy Subjects andin Patients with Liver Disease and Hepatocellular Carcinoma / Chapter 2.1 --- Introduction --- p.34 / Chapter 2.1.1. --- History of paracetamol --- p.34 / Chapter 2.1.2 --- Pharmacology of paracetamol --- p.37 / Chapter 2.1.3 --- "Absorption, Distribution, Metabolism and Excretion" --- p.38 / Chapter 2.1.3.1 --- Absorption --- p.38 / Chapter 2.1.3.2 --- Distribution --- p.41 / Chapter 2.1.3.3 --- Metabolism --- p.42 / Chapter 2.1.3.4 --- Excretion --- p.57 / Chapter 2.1.4 --- Toxicity and Overdosage --- p.59 / Chapter 2.2 --- Estimation of paracetamol and its metabolites in plasma and urine by high performance liquid chromatography --- p.72 / Chapter 2.2.1 --- Introduction --- p.72 / Chapter 2.2.2 --- Analytical method --- p.76 / Chapter 2.2.2.1 --- Materials --- p.76 / Chapter 2.2.2.2 --- Instrumentation --- p.77 / Chapter 2.2.2.3 --- Collection and storage of samples --- p.79 / Chapter 2.2.2.4 --- Chromatographic conditions --- p.79 / Chapter 2.2.3 --- Urine assay --- p.79 / Chapter 2.2.3.1 --- Preparation of standards and test samples for urine assay --- p.79 / Chapter 2.2.3.2 --- Calculation of results for urine assay --- p.80 / Chapter 2.2.3.3 --- Results of urine assay --- p.81 / Chapter 2.2.3.4 --- Validation of urine assay --- p.81 / Chapter 2.2.4 --- Plasma assay --- p.83 / Chapter 2.2.4.1 --- Preparation of standards and test samples for plasma assay --- p.83 / Chapter 2.2.4.2 --- Calculation of results for plasma assay --- p.91 / Chapter 2.2.4.3 --- Results of plasma assay --- p.91 / Chapter 2.2.4.4 --- Validation of plasma assay --- p.93 / Chapter 2.2.5 --- Summary --- p.99 / Chapter 2.3 --- The pharmacokinetics of paracetamol in healthy subjects --- p.103 / Chapter 2.3.1 --- Introduction --- p.103 / Chapter 2.3.2 --- Study protocol --- p.103 / Chapter 2.3.3 --- Methods --- p.103 / Chapter 2.3.3.1 --- Subjects --- p.103 / Chapter 2.3.3.2 --- Drug administration and sampling --- p.104 / Chapter 2.3.3.3 --- Drug analysis --- p.108 / Chapter 2.3.3.4 --- Calculations --- p.108 / Chapter 2.3.4 --- Pharmacokinetic analysis --- p.109 / Chapter 2.3.5 --- Statistical analysis --- p.113 / Chapter 2.3.6 --- Results --- p.114 / Chapter 2.3.6.1 --- Plasma Results --- p.114 / Chapter 2.3.6.2 --- Urine Results --- p.118 / Chapter 2.3.6.3 --- Pharmacokinetic Results --- p.125 / Chapter 2.3.6.4 --- Statistical Results --- p.134 / Chapter 2.3.7 --- Discussion --- p.145 / Chapter 2.4 --- "The pharmacokinetics of paracetamol in healthy subjects, patients with liver disease and hepatocellular carcinoma" --- p.155 / Chapter 2.4.1 --- Introduction --- p.155 / Chapter 2.4.2 --- Study protocol --- p.156 / Chapter 2.4.3 --- Methods --- p.156 / Chapter 2.4.3.1 --- Subjects --- p.156 / Chapter 2.4.3.2 --- Drug administration and sampling --- p.157 / Chapter 2.4.3.3 --- Drug analysis --- p.160 / Chapter 2.4.3.4 --- Calculations --- p.160 / Chapter 2.4.4 --- Pharmacokinetic analysis --- p.161 / Chapter 2.4.6 --- Results --- p.162 / Chapter 2.4.6.1 --- Plasma Results --- p.162 / Chapter 2.4.6.2 --- Urine Results --- p.162 / Chapter 2.4.6.3 --- Pharmacokinetic Results --- p.179 / Chapter 2.4.7 --- Discussion --- p.194 / Chapter 2.4.8 --- Summary --- p.203 / Chapter Chapter 3 --- Metabolic Activation of Aflatoxin B1 in Healthy Subjects and in Patients with Liver Disease and Hepatocellular Carcinoma / Chapter 3.1 --- General introduction --- p.206 / Chapter 3.1.1 --- Chemical structures and properties --- p.207 / Chapter 3.1.2 --- Contamination of food by aflatoxins --- p.209 / Chapter 3.1.3 --- Metabolism of aflatoxins --- p.210 / Chapter 3.1.4 --- Human diseases possibly related to exposure to aflatoxins --- p.226 / Chapter 3.1.4.1 --- Acute aflatoxicosis --- p.226 / Chapter 3.1.4.2 --- Reye's syndrome --- p.227 / Chapter 3.1.4.3 --- Kwashiorkor --- p.228 / Chapter 3.1.4.4 --- Impaired immune function --- p.229 / Chapter 3.1.4.5 --- Hepatocellular carcinoma --- p.230 / Chapter 3.1.5 --- Biochemical and molecular epidemiology of aflatoxins --- p.232 / Chapter 3.2 --- Development of an ELISA method to monitor AFB1 exposure in human serum --- p.237 / Chapter 3.2.1 --- Introduction --- p.237 / Chapter 3.2.2 --- Preparation of all the components necessary for analysing AFB1-albumin adducts by ELISA --- p.243 / Chapter 3.2.2.1 --- Materials --- p.243 / Chapter 3.2.2.2 --- Preparation of rabbit AFB1 antiserum --- p.244 / Chapter 3.2.2.3 --- Preparation of the rat monoclonal antibody --- p.244 / Chapter 3.2.2.4 --- Concentration of cell culture supernatant by ammonium sulphate precipitation --- p.246 / Chapter 3.2.2.5 --- Preparation of the BSA-AFB1 conjugate --- p.248 / Chapter 3.2.2.6 --- Preparation of the immunoaffinity gel --- p.250 / Chapter 3.2.2.7 --- Preparation of the ELISA plates --- p.251 / Chapter 3.2.3 --- General procedures used in the analysis of AFB1- albumin adducts --- p.252 / Chapter 3.2.3.1 --- Competitive ELISA binding assay --- p.253 / Chapter 3.2.3.2 --- Sep-pak C18 cartridge --- p.254 / Chapter 3.2.3.3 --- Immunoaffinity column --- p.255 / Chapter 3.2.3.4 --- Evaporation process --- p.255 / Chapter 3.2.3.5 --- HPLC --- p.256 / Chapter 3.2.3.6 --- Radioactive counting --- p.256 / Chapter 3.2.3.7 --- Albumin isolation --- p.257 / Chapter 3.2.3.8 --- Digestion of albumin --- p.257 / Chapter 3.2.3.9 --- Animal procedures --- p.258 / Chapter 3.2.4 --- Validations --- p.259 / Chapter 3.2.4.1 --- Analysis of standard AFB1 and AFB1- lysine in ELISA --- p.259 / Chapter 3 2.4.2 --- Optimisation of antiserum dilution and concentration of coating antigenin ELISA --- p.259 / Chapter 3 2.4.3 --- Elution characteristics and capacity of the immunoaffinity column --- p.261 / Chapter 3.2.4.4 --- Comparison of immunoaffinity gels prepared with different affinity gels --- p.261 / Chapter 3.2.4.5 --- Immunoaffinity column experiment of AFB1-lysine --- p.263 / Chapter 3.2.4.6 --- HPLC Analysis of fractions from immunoaffinity column --- p.263 / Chapter 3.2.4.8 --- HPLC analysis of fractions from Sep- Pak C18 cartridge --- p.264 / Chapter 3.2.4.9 --- Digestion of serum albumin by proteinase K --- p.264 / Chapter 3.2.4.10 --- Effect of ethanol in samples to be loaded onto Sep-Pak C18 cartridge --- p.265 / Chapter 3.2.4.11 --- Effect of drying in a vacuum concentrator on recovery of radioactivity of 3H-AFB1 --- p.266 / Chapter 3.2.4.12 --- Evaluation of the overall procedure for the analysis of serum albumin adducts of AFB1 --- p.267 / Chapter 3.2.4.13 --- HPLC analysis of samples obtained after digestion and all clean-up procedures --- p.268 / Chapter 3.2.5 --- Results and discussion --- p.268 / Chapter 3.2.5.1 --- BSA-AFB1 conjugate --- p.268 / Chapter 3.2.5.2 --- Treatment of experimental animals with 3H-AFB1 --- p.270 / Chapter 3.2.5.3 --- Optimisation of antiserum dilution and concentration of coating antigenin ELISA --- p.272 / Chapter 3.2.5.4 --- Analysis of standard AFB1 and AFB1- lysine in ELISA --- p.275 / Chapter 3.2.5.5 --- Sep-Pak C18 cartridge - elution characteristics and capacity --- p.279 / Chapter 3.2.5.6 --- Elution characteristics of immunoaffinity columns --- p.282 / Chapter 3.2.5.7 --- Immunoaffinity column experiment of AFB1-lysine --- p.290 / Chapter 3.2.5.8 --- Digestion of serum albumin by proteinase K --- p.295 / Chapter 3.2.5.9 --- Effect of ethanol in samples to be applied onto Sep-Pak C18 cartridges --- p.297 / Chapter 3.2.5.10 --- Recovery of radioactivity after dryingin a vacuum concentrator --- p.300 / Chapter 3.2.5.11 --- Recovery of the overall clean-up procedure for the analysis of serum albumin adducts of AFB1 --- p.300 / Chapter 3.2.5.12 --- HPLC analysis of samples obtained after all clean-up procedures --- p.305 / Chapter 3.2.5.13 --- The use of rabbit anti-AFB1 anti-serum and rat anti-AFB1 monoclonal antibody --- p.308 / Chapter 3.2.6 --- Summary --- p.309 / Chapter 3.3 --- Monitoring of AFBralbumin adducts in plasma of patients with liver disease and hepatocellular carcinoma --- p.311 / Chapter 3.3.1 --- Introduction --- p.311 / Chapter 3.3.2 --- Material and methods --- p.314 / Chapter 3.3.2.1 --- Subject --- p.314 / Chapter 3.3.2.2 --- Sample collections --- p.315 / Chapter 3.3.2.4 --- Assay for AFB1-albumin adducts --- p.315 / Chapter 3.3.2.5 --- Statistical analysis --- p.318 / Chapter 3.3.3 --- Results and discussion --- p.318 / Chapter Chapter 4 --- Summary and Ideas for Further Studies --- p.330 / Acknowledgements --- p.333 / References --- p.335 / Appendices --- p.364